Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29771862 | 0.82 | KMT2A (0.49) | MEN1KMT2AHTR2BGRM5AOC3 | |
| SCHEMBL27156530 | 0.81 | MEN1 (0.50) | MEN1KMT2AHTR2BGRM5HTR2A | |
| SCHEMBL30242496 | 0.80 | MEN1 (0.49) | MEN1KMT2AHTR2BCYP1A2CYP2D6 | |
| SCHEMBL28929559 | 0.80 | MEN1 (0.49) | MEN1KMT2AHTR2BCYP1A2CYP2D6 | |
| SCHEMBL25947321 | 0.78 | MEN1 (0.50) | MEN1KMT2AGRM5AOC3 | |
| SCHEMBL2205991 | 0.77 | MEN1 (0.69) | MEN1KMT2AGRM5 | |
| SCHEMBL30242551 | 0.77 | MEN1 (0.69) | MEN1KMT2AGRM5 | |
| SCHEMBL29771861 | 0.73 | MEN1 (0.52) | MEN1KMT2ACYP1A2CYP2D6GRM5 | |
| SCHEMBL25947347 | 0.73 | KDM4E (0.46) | HTR2BCYP1A2CYP2D6SLC6A4DRD3 | |
| SCHEMBL15727806 | 0.71 | HTR1A (0.50) | MEN1KMT2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | MEN1 2549/4885KMT2A 2987/4885HTR2B 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.